Error loading player: No playable sources found
FriCU12
Updates on CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas
Date
March 19, 2021
Learning Objectives
- Describe the current treatment approach and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
- Review the efficacy of currently approved as well as investigational CAR T-cell therapies for relapsed or refractory B-cell lymphomas.
- Evaluate the strategies for the management of unique toxicities associated with CAR T-cell therapies, and integrate CAR T-cell therapy into the overall treatment plan in appropriate patients with relapsed or refractory B-cell lymphomas.
Speaker
Abramson Cancer Center at the University of Pennsylvania
